Overview
Attorney Alexis Boaz brings her analytical skills and client-focused approach to represent and advise a diverse group of health care clients, including health plans, clinical laboratories, pharmaceutical companies, pharmacy chains, telehealth providers, medical device companies, hospitals and health systems, management services organizations, and other clients.
Alexis focuses her work on regulatory due diligence, regulatory counseling, and policy and legislative analysis. She walks clients through:
- plan and issuer-side compliance with the No Surprises Act, the Transparency in Coverage rules, and other requirements under the Consolidated Appropriations Act;
- provider and facility-side compliance with the No Surprises Act and state surprise and balance billing laws, particularly on matters impacting providers, facilities, and clinical laboratories;
- provider and facility compliance and implementation with “Good Faith Estimate” requirements, including with the preparation of customized forms;
- Medicare Advantage issues, including inquiries around marketing and supplemental benefits;
- prescription drug pricing and pharmacy issues;
- all health regulatory aspects of mergers, acquisitions, other health care transactions;
- state health care regulatory issues associated with change of ownership and Medicaid provider enrollment;
- health licensing issues for providers and facilities, including telehealth providers;
- legal and regulatory matters arising under Medicare, Medicaid and other third-party reimbursement programs, including coding, coverage, and payment;
- government inquiries and investigations;
- state and federal health care fraud and abuse laws and regulations; and
- regulatory analysis and advocacy for trade groups and other clients.
She also closely follows developments to keep clients up to date on surprise billing and prescription drug pricing matters, the individual marketplace, and developments in Medicare.
Clients know Alexis understands how legislative and regulatory changes affect health industry trends. Alexis’ prior experience across the public and private sectors and her in-depth knowledge of health policy and regulatory matters make her exceptionally qualified to navigate clients through the complexities of the health care regulatory landscape at the state and federal level. That experience includes interning in the U.S. Department of Health and Human Services in:
- the Office of General Counsel’s Centers for Medicare & Medicaid Services Division where she analyzed care models proposed by the Center for Medicare & Medicaid Innovation;
- the Office of Global Affairs’ Division for Trade and Health where she analyzed prescription drug pricing issues;
- the Office of General Counsel’s Public Health Division; and
- the Office of Inspector General’s Office of Evaluations and Inspections.
She also served as:
- a Health Policy Law Clerk for the U.S. Senate Committee on Finance;
- a Health Policy Fellow for the Congressional Black Caucus Foundation Health Braintrust in the U.S. House of Representatives; and
- a Health Policy Intern for the U.S. Senate Committee on Health, Education, Labor & Pensions.
She was also a Legal Intern in the Executive Office of the President during the Obama Administration. She has gained further exposure to other aspects of the health care industry through her work at a public policy think-tank; a nonprofit, academic health system in Tennessee; the Washington, D.C., Department of Health; an academic teaching hospital in Washington; and a national nonprofit public health charitable organization focused on fetal alcohol syndrome.
Alexis founded and co-leads Epstein Becker Green’s (“EBG’s”) “No Surprises Act Focused Initiative,” where she analyzes legal, operational, and other considerations of the No Surprises Act and related laws to assist clients across the health care industry. She previously co-led the “100 Days Initiative,” where she tracked and analyzed notable legislative, policy, and regulatory developments under the Biden Administration to help clients anticipate trends in health care. She has served as a contributing author of EBG’s Telemental Health Laws app, a comprehensive survey of state telehealth laws, regulations, and policies for mental and behavioral health practitioners and stakeholders across all 50 states, the District of Columbia, and Puerto Rico. She also contributes to the firm’s Health Law Advisor Blog and co-authors client alerts on new developments in health law and policy.
Read less
Focus Areas
Services
Industries
Trending Issues
Experience
Credentials
Education
- The George Washington University Law School (J.D.)
- Recipient, President’s Volunteer Service Award and GW Excellence in Service Award
- Certified Student Attorney, Health Insurance Counseling Project, GW Health Law Rights Clinic
- Capstone: “The State Stabilization of Health Markets Through Comprehensive Use of Coordinated Waivers, Reinsurance, a Public Option, and an Individual Mandate”
- President, Student Health Law Association
- The George Washington University (M.P.H.)
- Milken Institute School of Public Health
- Health Policy Concentration. Capstone: “Analysis of Trends in Stakeholder Responses to the International Pricing Index Advanced Notice for Proposed Rulemaking”
- Recipient, Chair’s Award, GW Department of Health Policy & Management
- President, Health Policy Student Association
- Georgetown University (B.S.)
- Health Care Management and Policy
Bar Admissions
- District of Columbia
Professional & Community Involvement
- Leadership Council on Legal Diversity, 2022 Pathfinder
Media
Events
Insights
Insights
- BlogsCMS Rules Propose Changes Regarding the Medicare Prescription Drug Inflation Rebate Program, Refundable Drugs, Skin ...13 minute read
- BlogsIt’s Been a Long Time Coming – FDA’s Final Rule on Regulation of Laboratory Developed Tests (LDTs) as Medical Devices ...8 minute read
- PublicationsAdvancing Interoperability and Improving Prior Authorization: No One Said It Would Be Easy!18 minute read
- BlogsLast Call for Comments on the Bipartisan Discussion Draft of the SUSTAIN Act: Shaping 340B for the Future10 minute read
- PublicationsCMS Seeks Stakeholder Feedback About Medicare Transaction Facilitator Services for the Medicare Drug Price Negotiation ...4 minute read
- BlogsCMS Names Its First Ten Negotiated Part D Drugs: Inflation Reduction Act Updates11 minute read
- PublicationsState Regulation of Pharmacy Benefit Managers: Tenth Circuit Holds That ERISA and Medicare Part D Preempt Key Parts of ...25 minute read
- BlogsTexas Federal Court Issues Fourth Ruling Invalidating Parts of the Administration’s No Surprises Act Regulations ...3 minute read
- BlogsIndependent Dispute Resolution Process Halted Following the Government's Third Major No Surprises Act-Related Loss in ...4 minute read
- BlogsTAKE TWO: CMS’s Second Attempt to Streamline Breakthrough Device Coverage Limited to 5 Devices Per Year26 minute read
- PublicationsCMS Releases Its List of 43 Part B Rebatable Drugs for Q3: Inflation Reduction Act Updates7 minute read
- PublicationsManufacturers Must Request Small Biotech Exception by July 3: Inflation Reduction Act Updates4 minute read
- PublicationsCMS Seeks Comment on Initial Guidance for the Part D Manufacturer Discount Program: Inflation Reduction Act Updates ...2 minute read
- BlogsMore Federal Action in the Pharmaceutical Sector as PBM Bill Advances in the Senate12 minute read
- PublicationsCMS Issues an Information Collection Request for the Drug Price Negotiation Process: Inflation Reduction Act Updates ...3 minute read
- BlogsCMS Forwards Its Health Equity Agenda Through Its Annual Prospective Payment System Rulemaking Process5 minute read
- PublicationsCMS Issues an Information Collection Request on Negotiation Data Elements: Inflation Reduction Act Updates3 minute read
- PublicationsCMS Issues New Guidance on Medicare Drug Price Negotiation Program: Inflation Reduction Act Updates2 minute read
- PublicationsCMS Releases Its List of 27 Part B Rebatable Drugs for Q2 of 2023: Inflation Reduction Act Updates3 minute read
- BlogsComments to CMS Guidance on the Medicare Prescription Drug Inflation Rebate Program Due March 11, 202310 minute read
- PublicationsNo Surprises Act: HHS Extends Enforcement Moratorium on Co-Provider & Co-Facility Good Faith Estimates5 minute read
- PublicationsOverview of the CMS Request for Information to Strengthen the Medicare Advantage Program2 minute read
- BlogsFederal District Court Vacates QPA Rebuttable Presumption Provisions of No Surprises Act Regulations4 minute read
- BlogsCMS Releases No Surprises Act State Enforcement Letters4 minute read
- Firm AnnouncementsEpstein Becker Green Reports Telemental Health’s Influence Grows Throughout COVID-19 Pandemic6 minute read
- PublicationsMore Surprises on Surprise Billing: Will Federal or State Law Control?2 minute read
- PublicationsThe No Surprises Act: New and Surprising Challenges for Clinical Laboratories3 minute read
- PublicationsThe No Surprises Act: A Look at the First Round of Federal Regulations on Surprise Billing3 minute read
- PublicationsMore Surprises on Surprise Billing: Will Federal or State Law Control?11 minute read
- PublicationsKey False Claims Act Developments Affecting the Health Care Industry: What We Learned in 2020 & Predictions for What We Can ...5 minute read
- PublicationsThe No Surprises Act: Implications for Health Plans, Health Care Facilities, and Health Care Providers19 minute read
- PublicationsFinalized HHS Drug Formulary Rebate Rule Faces Uncertain Future Under Biden Administration and Current Legal Challenge ...20 minute read
- PublicationsLowering Drug Prices with the Anti-Kickback Statute: Future and Impact of HHS Final Rule to Disrupt Drug Formulary Rebates ...2 minute read
- PublicationsFalse Claims Act Enforcement During the COVID-19 Pandemic and Beyond1 minute read
- Firm AnnouncementsEpstein Becker Green's Annual Telehealth Analysis Reports an Increase in Telemental Health Fraud6 minute read
- BlogsFalse Claims Act Enforcement During the COVID-19 Pandemic and Beyond22 minute read
- PublicationsPresident Trump Signs Executive Orders on Drug Pricing and Domestic Supply Chain Reform22 minute read
- PublicationsINSIGHT: Labs Must Follow Two Kickback Laws During Covid-192 minute read
- PublicationsNew and Pre-Existing Federal Waivers and Flexibilities Available to Health Care Providers During a National Emergency ...23 minute read
- Media CoverageLaw360's Hottest Firms and Stories Features Health Care FCA Trends Article by Epstein Becker Green Attorneys2 minute read
- PublicationsWhat Health Care FCA Trends Tell Us About the Year Ahead2 minute read
- BlogsDOJ False Claims Act Recoveries FY 2019: Total Collections Rise – Almost 90 Percent Relate to Health Care5 minute read
- BlogsNew Program Integrity Rule Expanding Medicare Revocation and Denial Authorities Takes Effect Today17 minute read
- PublicationsHHS’s Regulatory Sprint to Coordinated Care – Part 2: OIG Issues Long-Awaited Proposed Rules34 minute read
- Firm AnnouncementsEpstein Becker Green Finds Increasing Acceptance of Telehealth Services Among Providers and Legislators8 minute read
- PublicationsSafeguarding America’s Health System from Sabotage
- PublicationsHealth Reform at the Crossroads: Progress or Peril?
- PublicationsAccountable Care Organization Summit: A White Paper on Findings, Outcomes, and Challenges
- PublicationsThe Management of Type II Diabetes Mellitus in the Face of the Healthcare System and Social Determinants